BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park SH, Won HJ, Kim SY, Shin YM, Kim PN, Yoon SM, Park JH, Kim JH. Efficacy and safety of ultrasound-guided implantation of fiducial markers in the liver for stereotactic body radiation therapy. PLoS One 2017;12:e0179676. [PMID: 28636658 DOI: 10.1371/journal.pone.0179676] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Akasaka H, Mizonobe K, Oki Y, Uehara K, Nakayama M, Tamura S, Munetomo Y, Kawaguchi H, Ishida J, Harada A, Ishihara T, Kubota H, Kawaguchi H, Sasaki R, Mayahara H. Fiducial marker position affects target volume in stereotactic lung irradiation. J Appl Clin Med Phys 2022;:e13596. [PMID: 35377962 DOI: 10.1002/acm2.13596] [Reference Citation Analysis]
2 Masuda S, Tsukiyama T, Minagawa Y, Koizumi K, Kako M, Kinbara T, Haruki U. Hepatocellular carcinoma effective stereotactic body radiotherapy using Gold Anchor and the Synchrony system: Two case reports and review of literature. World J Clin Cases 2022; 10(8): 2591-2603 [DOI: 10.12998/wjcc.v10.i8.2591] [Reference Citation Analysis]
3 Kato Y, Kamomae T, Kumagai M, Oie Y, Noguchi Y, Okudaira K, Kawamura M, Taoka T, Naganawa S. Hybrid 3D T1-weighted gradient-echo sequence for fiducial marker detection and tumor delineation via magnetic resonance imaging in liver stereotactic body radiation therapy. Physica Medica 2022;95:9-15. [DOI: 10.1016/j.ejmp.2022.01.003] [Reference Citation Analysis]
4 van de Lindt A, Nowee B, Janssen T, Schneider C, Remeijer P, van Pelt VWJ, Betgen A, Jansen EPM, Sonke JJ. Technical feasibility and clinical evaluation of 4D-MRI guided liver SBRT on the MR-linac. Radiother Oncol 2022:S0167-8140(22)00013-5. [PMID: 35033603 DOI: 10.1016/j.radonc.2022.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kibe Y, Takeda A, Tsurugai Y, Eriguchi T, Oku Y, Kimura Y, Nakamura N. Feasibility of marker-less stereotactic body radiotherapy for hepatocellular carcinoma. Acta Oncol 2022;61:104-10. [PMID: 34788194 DOI: 10.1080/0284186X.2021.2001566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kord M, Kluge A, Kufeld M, Kalinauskaite G, Loebel F, Stromberger C, Budach V, Gebauer B, Acker G, Senger C. Risks and Benefits of Fiducial Marker Placement in Tumor Lesions for Robotic Radiosurgery: Technical Outcomes of 357 Implantations. Cancers (Basel) 2021;13:4838. [PMID: 34638321 DOI: 10.3390/cancers13194838] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Gaspard D, Boujaoude Z, Kubicek G, Abouzgheib W. Transthoracic placement of fiducials with ultrasound or electronic navigational bronchoscopy needle guidance by the interventional pulmonologist: A case series. Respirol Case Rep 2021;9:e0818. [PMID: 34336221 DOI: 10.1002/rcr2.818] [Reference Citation Analysis]
8 Tokunaga K, Furuta A, Iizuka Y, Isoda H, Togashi K. Utility of real-time image fusion technology in ultrasonography-guided fiducial marker implantation for stereotactic body radiation therapy for liver tumors. Acta Radiol 2021;62:567-73. [PMID: 32586122 DOI: 10.1177/0284185120934479] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Khullar K, Dhawan ST, Nosher J, Jabbour SK. Fiducial marker migration following computed tomography-guided placement in the liver: a case report. AME Case Rep 2021;5:15. [PMID: 33912804 DOI: 10.21037/acr-20-153] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Dutta D, Kataki KJ, George S, Reddy SK, Sashidharan A, Kannan R, Madhavan R, Nair H, Tatineni T, Holla R. Prospective evaluation of fiducial marker placement quality and toxicity in liver CyberKnife stereotactic body radiotherapy. Radiat Oncol J 2020;38:253-61. [PMID: 33249803 DOI: 10.3857/roj.2020.00472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Gani C, Boeke S, McNair H, Ehlers J, Nachbar M, Mönnich D, Stolte A, Boldt J, Marks C, Winter J, Künzel LA, Gatidis S, Bitzer M, Thorwarth D, Zips D. Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac - Feasibility, workflow data and patient acceptance. Clin Transl Radiat Oncol 2021;26:55-61. [PMID: 33319073 DOI: 10.1016/j.ctro.2020.11.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
12 Deschamps F, Ronot M, Gelli M, Durand-labrunie J, Tazdait M, Hollebecque A, Dartigues P, de Baere T, Tselikas L. Interventional Radiology for Colorectal Liver Metastases. Curr Colorectal Cancer Rep 2020;16:29-37. [DOI: 10.1007/s11888-020-00449-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Morita R, Abo D, Sakuhara Y, Soyama T, Katoh N, Miyamoto N, Uchinami Y, Shimizu S, Shirato H, Kudo K. Percutaneous insertion of hepatic fiducial true-spherical markers for real-time adaptive radiotherapy. Minimally Invasive Therapy & Allied Technologies 2020;29:334-43. [DOI: 10.1080/13645706.2019.1663217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Scher N, Bollet M, Bouilhol G, Tannouri R, Khemiri I, Vouillaume A, Sellami N, Von Eyben R, Vannetzel JM, Darmon I, Rotenberg L, Lamallem H, Bauduceau O, Foster D, Toledano A. Safety and efficacy of fiducial marker implantation for robotic stereotactic body radiation therapy with fiducial tracking. Radiat Oncol 2019;14:167. [PMID: 31519194 DOI: 10.1186/s13014-019-1373-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
15 Riou O, Valdenaire S, Debuire P, Fenoglietto P, Debrigode C, Mazard T, Assenat É, Aillères N, Azria D. [Liver stereotactic body radiotherapy: Clinical features and technical consequences, results. Which treatment machine in which situation?]. Cancer Radiother 2019;23:636-50. [PMID: 31444078 DOI: 10.1016/j.canrad.2019.07.159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
16 Nakayama M, Uehara K, Nishimura H, Tamura S, Munetomo Y, Tsudou S, Mayahara H, Mukumoto N, Geso M, Sasaki R. Retrospective assessment of a single fiducial marker tracking regimen with robotic stereotactic body radiation therapy for liver tumours. Rep Pract Oncol Radiother 2019;24:383-91. [PMID: 31297039 DOI: 10.1016/j.rpor.2019.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
17 Soni PD, Palta M. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current State and Future Opportunities. Dig Dis Sci 2019;64:1008-15. [DOI: 10.1007/s10620-019-05539-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Lee S, Kim H, Ji Y, Cho B, Kim SS, Jung J, Kwak J, Park JH, Lee SW, Kim JH, Yoon SM. Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration. Sci Rep 2018;8:16224. [PMID: 30385839 DOI: 10.1038/s41598-018-34676-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
19 Park J, Jung J, Kim D, Jung IH, Park JH, Kim JH, Lee SW, Yoon SM. Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma. BMC Cancer 2018;18:1040. [PMID: 30367606 DOI: 10.1186/s12885-018-4953-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 van de Lindt T, Sonke JJ, Nowee M, Jansen E, van Pelt V, van der Heide U, Fast M. A Self-Sorting Coronal 4D-MRI Method for Daily Image Guidance of Liver Lesions on an MR-LINAC. Int J Radiat Oncol Biol Phys 2018;102:875-84. [PMID: 30054104 DOI: 10.1016/j.ijrobp.2018.05.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
21 Shibata S, Takamatsu S, Yamamoto K, Mizuhata M, Bou S, Sato Y, Kawamura M, Asahi S, Tameshige Y, Maeda Y, Sasaki M, Kumano T, Kobayashi S, Tamamura H, Gabata T. Proton Beam Therapy without Fiducial Markers Using Four-Dimensional CT Planning for Large Hepatocellular Carcinomas. Cancers (Basel) 2018;10:E71. [PMID: 29538310 DOI: 10.3390/cancers10030071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]